Transcriptome level analysis in Rett syndrome using human samples from different tissues

The mechanisms of neuro-genetic disorders have been mostly investigated in the brain, however, for some pathologies, transcriptomic analysis in multiple tissues represent an opportunity and a challenge to understand the consequences of the genetic mutation. This is the case for Rett Syndrome (RTT): a neurodevelopmental disorder predominantly affecting females that is characterised by a loss of purposeful movements and language accompanied by gait abnormalities and hand stereotypies. Although the genetic aetiology is largely associated to Methyl CpG binding protein 2 (MECP2) mutations, linking the pathophysiology of RTT and its clinical symptoms to direct molecular mechanisms has been difficult.One approach used to study the consequences of MECP2 dysfunction in patients, is to perform transcriptomic analysis in tissues derived from RTT patients or Induced Pluripotent Stem cells. The growing affordability and efficiency of this approach has led to a far greater understanding of the complexities of RTT syndrome but is also raised questions about previously held convictions such as the regulatory role of MECP2, the effects of different molecular mechanisms in different tissues and role of X Chromosome Inactivation in RTT.In this review we consider the results of a number of different transcriptomic analyses in different patients-derived preparations to unveil specific trends in differential gene expression across the studies. Although the analyses present limitations- such as the limited sample size- overlaps exist across these studies, and they report dysregulations in three main categories: dendritic connectivity and synapse maturation, mitochondrial dysfunction, and glial cell activity.These observations have a direct application to the disorder and give insights on the altered mechanisms in RTT, with implications on potential diagnostic criteria and treatments.

[1]  Jonathan Pevsner,et al.  FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. , 2007, Human molecular genetics.

[2]  James C. Cronk,et al.  Wild type microglia arrest pathology in a mouse model of Rett syndrome , 2012, Nature.

[3]  A. Bird,et al.  Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. , 1993, Nucleic acids research.

[4]  James C. Cronk,et al.  The role of microglia in brain maintenance: implications for Rett syndrome. , 2013, Trends in immunology.

[5]  David A. Orlando,et al.  Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. , 2013, Cell stem cell.

[6]  G. Valacchi,et al.  Genes Related to Mitochondrial Functions, Protein Degradation, and Chromatin Folding Are Differentially Expressed in Lymphomonocytes of Rett Syndrome Patients , 2013, Mediators of inflammation.

[7]  G. Ananiev,et al.  Isogenic Pairs of Wild Type and Mutant Induced Pluripotent Stem Cell (iPSC) Lines from Rett Syndrome Patients as In Vitro Disease Model , 2011, PloS one.

[8]  O. Dreesen,et al.  Unexpected X chromosome skewing during culture and reprogramming of human somatic cells can be alleviated by exogenous telomerase. , 2011, Cell stem cell.

[9]  Katharina Dietrich,et al.  Systemic Radical Scavenger Treatment of a Mouse Model of Rett Syndrome: Merits and Limitations of the Vitamin E Derivative Trolox , 2016, Front. Cell. Neurosci..

[10]  N. Kaya,et al.  Genomic and transcriptomic analyses distinguish classic Rett and Rett-like syndrome and reveals shared altered pathways. , 2011, Genomics.

[11]  H. Zoghbi,et al.  Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome , 2008, Neurology.

[12]  B. Antalffy,et al.  Decreased Dendritic Branching in Frontal, Motor and Limbic Cortex in Rett Syndrome Compared with Trisomy 21 , 1998, Journal of neuropathology and experimental neurology.

[13]  E. Schon,et al.  Neuronal degeneration and mitochondrial dysfunction. , 2003, The Journal of clinical investigation.

[14]  T. E. Morgan,et al.  Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro , 2005, Journal of neurochemistry.

[15]  K. Jellinger,et al.  Neuropathology of Rett syndrome. , 1988, Acta neuropathologica.

[16]  Paul H Lerou,et al.  Generation of human-induced pluripotent stem cells , 2008, Nature Protocols.

[17]  S. Nelson,et al.  Cell-Type-Specific Repression by Methyl-CpG-Binding Protein 2 Is Biased toward Long Genes , 2014, The Journal of Neuroscience.

[18]  J. Christodoulou,et al.  Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain , 2010, BMC Neuroscience.

[19]  G. Mandel,et al.  MeCP2 Is Critical for Maintaining Mature Neuronal Networks and Global Brain Anatomy during Late Stages of Postnatal Brain Development and in the Mature Adult Brain , 2012, The Journal of Neuroscience.

[20]  A. Bird,et al.  Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes , 2016, Human molecular genetics.

[21]  J. Arunachalam,et al.  MeCP2270 Mutant Protein Is Expressed in Astrocytes as well as in Neurons and Localizes in the Nucleus , 2010, Cytogenetic and Genome Research.

[22]  A. Scheibel,et al.  Neuropathology of Rett Syndrome: Case Report With Neuronal and Mitochondrial Abnormalities in the Brain , 1994, Journal of child neurology.

[23]  Eric P. Hoffman,et al.  Gene Expression Profiling in Postmortem Rett Syndrome Brain: Differential Gene Expression and Patient Classification , 2001, Neurobiology of Disease.

[24]  S. Skinner,et al.  Rett Syndrome: North American Database , 2007, Journal of child neurology.

[25]  J B Schulz,et al.  Glutathione, oxidative stress and neurodegeneration. , 2000, European journal of biochemistry.

[26]  T. Matsuishi,et al.  Alterations of Gene Expression and Glutamate Clearance in Astrocytes Derived from an MeCP2-Null Mouse Model of Rett Syndrome , 2012, PloS one.

[27]  D. Armstrong,et al.  The neuropathology of the Rett syndrome. , 1992, Brain & development.

[28]  M. Rastegar,et al.  Brain Region-Specific Expression of MeCP2 Isoforms Correlates with DNA Methylation within Mecp2 Regulatory Elements , 2014, PloS one.

[29]  J. Opitz,et al.  Rett syndrome: genetic clues based on mitochondrial changes in muscle. , 1989, American journal of medical genetics.

[30]  G. Valacchi,et al.  Systemic oxidative stress in classic Rett syndrome. , 2009, Free radical biology & medicine.

[31]  David P. Kreil,et al.  The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance , 2014, Nature Biotechnology.

[32]  R. Gambari,et al.  Cytokines profile and peripheral blood mononuclear cells morphology in Rett and autistic patients. , 2016, Cytokine.

[33]  W. Kaufmann,et al.  Rett syndrome: Revised diagnostic criteria and nomenclature , 2010, Annals of neurology.

[34]  G. Valacchi,et al.  Scavenger receptor B1 post‐translational modifications in Rett syndrome , 2013, FEBS letters.

[35]  W. Kaufmann,et al.  Selective Cerebral Volume Reduction in Rett Syndrome: A Multiple-Approach MR Imaging Study , 2008, American Journal of Neuroradiology.

[36]  C. Masters,et al.  Rett syndrome: abnormal membrane-bound lamellated inclusions in neurons and oligodendroglia. , 1988, American journal of medical genetics.

[37]  W. Kaufmann,et al.  MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution , 2005, Brain and Development.

[38]  J. Pronk,et al.  Reproducibility of Oligonucleotide Microarray Transcriptome Analyses , 2002, The Journal of Biological Chemistry.

[39]  A. Bittner,et al.  Comparison of RNA-Seq and Microarray in Transcriptome Profiling of Activated T Cells , 2014, PloS one.

[40]  A. Bird,et al.  MeCP2 Is a Transcriptional Repressor with Abundant Binding Sites in Genomic Chromatin , 1997, Cell.

[41]  Meredith Wilson,et al.  The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy , 2012, European Journal of Human Genetics.

[42]  G. Cevenini,et al.  Diagnostic criteria for the Zappella variant of Rett syndrome (the preserved speech variant) , 2009, Brain and Development.

[43]  S. Coker,et al.  Rett Syndrome and Mitochondrial Enzyme Deficiencies , 1991, Journal of child neurology.

[44]  S. Kudo.  Methyl-CpG-Binding Protein MeCP2 Represses Sp1-Activated Transcription of the Human Leukosialin Gene When the Promoter Is Methylated , 1998, Molecular and Cellular Biology.

[45]  Huan Wang,et al.  Neuronal Interleukin-4 as a Modulator of Microglial Pathways and Ischemic Brain Damage , 2015, The Journal of Neuroscience.

[46]  H. Zoghbi,et al.  Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. , 2002, Human molecular genetics.

[47]  D. Harvey,et al.  Rett Syndrome Astrocytes Are Abnormal and Spread MeCP2 Deficiency through Gap Junctions , 2009, The Journal of Neuroscience.

[48]  L. Pozzo-Miller,et al.  Dendritic spine dysgenesis in Rett syndrome , 2014, Front. Neuroanat..

[49]  A. Bird,et al.  DNA methylation specifies chromosomal localization of MeCP2 , 1996, Molecular and cellular biology.

[50]  Michael J. Yetman,et al.  Wild-type microglia do not reverse pathology in mouse models of Rett syndrome , 2015, Nature.

[51]  A. Reiss,et al.  Neuroanatomy of Rett syndrome: A volumetric imaging study , 1993, Annals of neurology.

[52]  H. Zoghbi,et al.  Karyopherin α 3 and Karyopherin α 4 Proteins Mediate the Nuclear Import of Methyl-CpG Binding Protein 2* , 2015, The Journal of Biological Chemistry.

[53]  H. Zoghbi,et al.  Brief Report: MECP2 Mutations in People Without Rett Syndrome , 2014, Journal of autism and developmental disorders.

[54]  Noriyuki Kishi,et al.  MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions , 2004, Molecular and Cellular Neuroscience.

[55]  W. Kaufmann,et al.  Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome , 2014, Journal of Medical Genetics.

[56]  J. Rothstein,et al.  Glutamate transporter expression and function in human glial progenitors , 2004, Glia.

[57]  S. Ojeda,et al.  Correcting deregulated Fxyd1 expression ameliorates a behavioral impairment in a mouse model of Rett syndrome , 2013, Brain Research.

[58]  K. Gordon,et al.  Male Rett syndrome variant: application of diagnostic criteria. , 1999, Pediatric neurology.

[59]  Thomas Sommer,et al.  Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system. , 2014, Biochimica et biophysica acta.

[60]  J. Raber,et al.  A role for glia in the progression of Rett’s syndrome , 2011, Nature.

[61]  Christina Thaller,et al.  Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus , 2009, Human molecular genetics.

[62]  H. Sarnat.  Clinical neuropathology practice guide 5-2013: markers of neuronal maturation , 2013, Clinical neuropathology.

[63]  David P. Kreil,et al.  A comprehensive study design reveals treatment-and transcript abundance – dependent concordance between RNA-seq and microarray data , 2014 .

[64]  P. Fisher,et al.  Role of Excitatory Amino Acid Transporter‐2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics , 2011, Journal of cellular physiology.

[65]  Sherman Morton Weissman,et al.  Transcriptional regulation in pluripotent stem cells by methyl CpG-binding protein 2 (MeCP2). , 2014, Human molecular genetics.

[66]  R. Edwards,et al.  Transcriptome analysis of human brain tissue identifies reduced expression of complement complex C1Q Genes in Rett syndrome , 2016, BMC Genomics.

[67]  A. Antonietti,et al.  Recent insights into genotype-phenotype relationships in patients with Rett syndrome using a fine grain scale. , 2014, Research in developmental disabilities.

[68]  S. Melov,et al.  Mitochondrial disease in mouse results in increased oxidative stress. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[69]  E. Masliah,et al.  Widespread changes in dendritic and axonal morphology in Mecp2‐mutant mouse models of rett syndrome: Evidence for disruption of neuronal networks , 2009, The Journal of comparative neurology.

[70]  A. Bird,et al.  Gene Expression Analysis Exposes Mitochondrial Abnormalities in a Mouse Model of Rett Syndrome , 2006, Molecular and Cellular Biology.

[71]  F. Bianchi,et al.  Rett syndrome: a wide clinical and autonomic picture , 2016, Orphanet Journal of Rare Diseases.

[72]  J. Strouboulis,et al.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription , 1998, Nature Genetics.

[73]  H. Okano,et al.  Differentiation of multipotent neural stem cells derived from Rett syndrome patients is biased toward the astrocytic lineage , 2015, Molecular Brain.

[74]  Martin J. Aryee,et al.  Epigenetic memory in induced pluripotent stem cells , 2010, Nature.

[75]  J Dragich,et al.  Rett syndrome: a surprising result of mutation in MECP2. , 2000, Human molecular genetics.

[76]  David Baltimore,et al.  NF-κB functions in synaptic signaling and behavior , 2003, Nature Neuroscience.

[77]  M. D'Esposito,et al.  Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome , 2014, Neurobiology of Disease.

[78]  B. Hagberg,et al.  "Forme fruste" of Rett syndrome--a case report. , 1986, American journal of medical genetics. Supplement.

[79]  S. Kyrylenko,et al.  Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells , 2005, Neurochemistry International.

[80]  L. Opitz,et al.  Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome , 2012, Neurobiology of Disease.

[81]  Marianna Aprile,et al.  RNA-Seq and human complex diseases: recent accomplishments and future perspectives , 2012, European Journal of Human Genetics.

[82]  P. Huppke,et al.  MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. , 2001, American journal of human genetics.

[83]  M. D'Esposito,et al.  Increased levels of 4HNE-protein plasma adducts in Rett syndrome. , 2011, Clinical biochemistry.

[84]  Fred H. Gage,et al.  A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells , 2010, Cell.

[85]  Tianlin Cheng,et al.  Conditional deletion of Mecp2 in parvalbumin-expressing GABAergic cells results in the absence of critical period plasticity , 2014, Nature Communications.

[86]  George Perry,et al.  Oxidative Stress and Neurodegeneration , 2005, Annals of the New York Academy of Sciences.

[87]  J. Christodoulou,et al.  Rett Syndrome: A Genetic Update and Clinical Review Focusing on Comorbidities. , 2017, ACS chemical neuroscience.

[88]  M. Fagiolini,et al.  Visual evoked potentials detect cortical processing deficits in Rett syndrome , 2015, Annals of neurology.

[89]  B. Hagberg.  Clinical manifestations and stages of Rett syndrome. , 2002, Mental retardation and developmental disabilities research reviews.

[90]  G. Mandel,et al.  Non–cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology , 2009, Nature Neuroscience.

[91]  L. Carrel,et al.  X-Chromosome Inactivation in Rett Syndrome Human Induced Pluripotent Stem Cells , 2012, Front. Psychiatry.

[92]  J. Charrow,et al.  Increased Wnt and Notch signaling: a clue to the renal disease in Schimke immuno-osseous dysplasia? , 2016, Orphanet Journal of Rare Diseases.

[93]  R. Weksberg,et al.  Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation , 2011, Human molecular genetics.

[94]  J. Galano,et al.  Cytokine Dysregulation in MECP2- and CDKL5-Related Rett Syndrome: Relationships with Aberrant Redox Homeostasis, Inflammation, and ω-3 PUFAs , 2015, Oxidative medicine and cellular longevity.

[95]  K. Hochedlinger,et al.  Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells , 2010, Nature Biotechnology.

[96]  Izumi Maezawa,et al.  Rett Syndrome Microglia Damage Dendrites and Synapses by the Elevated Release of Glutamate , 2010, The Journal of Neuroscience.

[97]  B. Molyneaux,et al.  Reduction of aberrant NF-κB signalling ameliorates Rett syndrome phenotypes in Mecp2-null mice , 2016, Nature Communications.

[98]  H. Leonard,et al.  Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome , 2016, Orphanet Journal of Rare Diseases.

[99]  D. Butterfield,et al.  Oxidative stress and neurodegeneration , 2017, Brain Research Bulletin.

[100]  J Christodoulou,et al.  Refining the phenotype of common mutations in Rett syndrome , 2004, Journal of Medical Genetics.

[101]  R. Cantor,et al.  Phenotypic manifestations of MECP2 mutations in classical and atypical rett syndrome , 2004, American journal of medical genetics. Part A.

[102]  J. Christodoulou,et al.  RettBASE: Rett syndrome database update , 2017, Human mutation.

[103]  J. Tolmie,et al.  CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients , 2006, Journal of Medical Genetics.

[104]  T. Hasegawa,et al.  A 2.0 Mb microdeletion in proximal chromosome 14q12, involving regulatory elements of FOXG1, with the coding region of FOXG1 being unaffected, results in severe developmental delay, microcephaly, and hypoplasia of the corpus callosum. , 2013, European journal of medical genetics.